Citations

Clear

862 citation(s) found for "Habermann, EB".

The Association of Extended Venous Thromboembolism Prophylaxis and Venous Thromboembolism After Cancer Surgery
Tan, Po Hong, Lillemoe, Keith D., Stucky, Chee-Chee, Brady, Justin T., Pockaj, Barbara A. , Cronin, Patricia, Potter, Alexandra L. , Yang, Chi-Fu Jeffrey, Mavros, Michail N., Fagenholz, Peter J. , Kastrinakis, William V., Poruk, Katherine E. , Wasif, Nabil , Qadan, M., Pockaj, Barbara, Poruk, Katherine, Fong, Zhi Ven , Lillemoe, Keith D. , Stucky, Chee-Chee, Brady, Justin T. , Cronin, Patricia, Linderman, George C. , Yang, Chi‐Fu Jeffrey , Mavros, Michail N. , Thiels, Cornelius A. , Habermann, Elizabeth B. , Chang, Yu‐Hui , Qadan, Motaz

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 19, 2026 | Volume: 24 | Issue: 4 | Pages: No page available

10.6004/jnccn.2025.7128 | PMID 41911913 Get It

Background: ASCO recommends extended venous thromboembolism (VTE) prophylaxis with low-molecular-weight heparin (LMWH) or direct oral anticoagulants (DOACs) following cancer surgery. However, these recommendations were based on trials using routine venography, which detects asymptomatic VTEs, and real-life efficacy is not well studied. We aimed to assess the association of extended VTE prophylaxis with the incidence of clinically significant VTE after elective cancer surgery. Patients and Methods: In this retrospective, population-based cohort study, we identified patients who underwent surgical resection for lung, breast, esophageal, gastric, pancreas, and colon cancer from 2010 to 2017 using the SEER–Medicare linked dataset. Patients were divided into 1 of 2 main groups for comparative analyses: those who received extended VTE prophylaxis after cancer surgery and those who did not. Patients who received extended VTE prophylaxis after cancer surgery were identified as those prescribed prophylactic doses of LMWH or a DOAC within 7 days of discharge, as captured in Medicare Part D files. Results: A total of 113,739 Medicare beneficiaries were identified, of whom 1,570 (1.4%) received extended VTE prophylaxis. There was a year-over-year increase in the use of extended VTE prophylaxis during the study period, rising from 0.6% in 2010 to 3.3% in 2017. The overall incidence of VTE was 1.6% at 1 month, 4.3% at 6 months, 5.7% at 12 months, with significant differences observed across cancer types ( P <.001). However, patients who received extended VTE prophylaxis had a higher 1-year cumulative incidence of postoperative VTE compared with those who did not (11.4% vs 5.3%; P <.001), an association that was consistent across cancer sites. In adjusted analyses, extended VTE prophylaxis was independently associated with an increased risk of VTE (hazard ratio, 1.6; 95% CI, 1.3–2.0; P <.001). Extended prophylaxis was also associated with a higher 1-year incidence of bleeding events compared with patients who did not receive prophylaxis (12.0% vs 8.5%; P <.001). Conclusions: The utilization of extended VTE prophylaxis after cancer surgery remains low, although it has increased every year. Paradoxically, patients who received extended VTE prophylaxis had higher incidences of clinically significant VTE and bleeding compared with those who did not, likely reflecting patient selection and surveillance bias after surgery. In light of these findings, national guidelines recommending postoperative extended VTE prophylaxis, and its use as a surrogate for quality of care, should continue to be re-examined.
Family history of haematological malignancy and prognosis across non‐Hodgkin lymphoma subtypes
Cholack, George , Mwangi, Raphael , Vodička, Prokop , Habermann, Thomas M., Hinder, Verena , Robinson, Dennis P. , Feldman, Andrew L., Witzig, T.E. , Villasboas, Jose C., Ansell, Stephen M., Wang, Yucai, Thompson, Carrie A. , Slager, Susan L., Maurer, Matthew, Novak, Anne J. , Cerhan, James R., Witzig, Thomas E. , Habermann, Thomas M. , Cholack, George A , Habermann, Thomas , Ansell, Stephen M , Wang, Yucai , Slager, Susan L , Maurer, Matthew , Novak, Anne J , Cerhan, James R , Feldman, Andrew L. , Ansell, Stephen M. , Link, Brian K. , Wang, Yucai , Slager, Susan L. , Cerhan, James R. , Vodicka, Prokop

Mayo Clinic

British Journal of Haematology | March 10, 2026 | Volume: 208 | Issue: 5 | Pages: 1631-1640

10.1111/bjh.70397 | PMID 41806244 Get It

Summary Family history of haematological malignancy (FHHM) reflects inherited susceptibility to non‐Hodgkin lymphoma (NHL), but its prognostic significance remains poorly understood. We used a cohort study of 1994 NHL patients to evaluate associations between FHHM and clinical outcomes across lymphoma subtypes. We estimated associations, adjusted for sex and lymphoma‐specific prognostic index, of self‐reported FHHM in a first‐degree relative with overall survival (OS), event‐free survival (EFS) and lymphoma‐specific survival (LSS) using multivariable Cox regression models and with failure to achieve EFS at 24 months (EFS24) using logistic regression. FHHM prevalence was 12.8%, and the median follow‐up among survivors was 12.0 years. FHHM was not associated with OS. In subtype‐specific analyses, FHHM was associated with inferior LSS (hazard ratio [HR] = 1.98, 95% confidence interval [CI] 1.11–3.53) in follicular lymphoma (FL); this association and the association with EFS24 failure strengthened among those treated with front‐line immunochemotherapy (EFS24 failure odds ratio = 2.57, 95% CI 1.08–5.99; LSS HR = 2.68, 95% CI 1.09–6.58). In mantle cell lymphoma, FHHM was associated with inferior EFS (HR = 1.70, 95% CI 1.02–2.85). Interaction testing did not demonstrate significant heterogeneity of FHHM effects by lymphoma subtype. FHHM may be associated with adverse outcomes in select NHL groups, particularly FL. These findings warrant further investigation of germline and environmental factors potentially contributing to more aggressive FLs.
Anatomical Localization–Based Analysis of Relapsed Secondary Central Nervous System Aggressive B‐Cell Lymphoma (R‐SCNSL)
Okcu, Izel, Wang, Yucai, Li, Z., White, Launia J. , Johnston, Patrick B., Paludo, Jonas, King, Rebecca L., Witzig, Thomas E., Habermann, Thomas M., Nowakowski, Grzegorz S. , Witzig, Thomas E. , Habermann, Thomas M. , Li, Zhuo , Wang, Yucai , Witzig, T.E. , Okcu, Izel , Wang, Yucai , Rosenthal, Allison C, Habermann, Thomas , Johnston, Patrick B. , Rosenthal, Allison , Paludo, Jonas , King, Rebecca L., Tun, Han W.

Mayo Clinic

Hematological Oncology | March 8, 2026 | Volume: 44 | Issue: 2 | Pages: No page available

10.1002/hon.70182 | PMID 41794414 Get It

ABSTRACT 162 patients with relapsed secondary central nervous system lymphoma (R‐SCNSL) (median age, 65 years; male, 59.9%) including central nervous system (CNS)‐only ( n = 120) and concomitant CNS/systemic relapse ( n = 42) were retrospectively analyzed. Overall, 21.9% of patients were classified as high risk according to the CNS International Prognostic Index (CNS‐IPI). Several biological and clinical features were significantly associated with leptomeningeal involvement, including double‐ or triple‐hit (DHL/THL) status, MYC rearrangement, negative BCL6 expression by IHC, bone marrow involvement, and concomitant R‐SCNSL. Multivariable analysis showed that leptomeningeal involvement independently predicted inferior OS and was associated with a 98% increase in the hazard of death compared with parenchymal relapse (HR = 1.98, 95% CI: 1.20–3.26, p = 0.008). Based on anatomical localization, R‐SCNSL was classified into four subtypes: parenchymal‐only involvement (parenchymal‐CNS [P‐CNS], 68/42%) and parenchymal involvement plus systemic relapse (parenchymal‐concomitant [P‐concomitant], 17/10.5%); and leptomeningeal with or without parenchymal involvement (leptomeningeal‐CNS [LM‐CNS], 52/32.1%) and leptomeningeal with systemic relapse (leptomeningeal‐concomitant [LM‐concomitant], 25/15.4%). This anatomical classification significantly impacted OS and PFS ( p < 0.001). Two‐year OS and PFS were 58.2% and 29.1% for P‐CNS, 32.4% and 17.7% for P‐concomitant, 22% and 13.9% for LM‐CNS, and 7.1% and 0% for LM‐concomitant, respectively. ASCT showed a trend toward improved survival among patients with a response (CR/PR) in a 4‐month landmark analysis. These findings support the clinical application of the anatomical classification in the management of R‐SCNSL.
Limited discriminatory performance of the iMCD-IPI in a Western cohort
Nishimura, Yoshito, Nishimura, Yoshito , Nishimura, Yoshito , Habermann, Thomas M. , Dispenzieri, Angela

Mayo Clinic

The Oncologist | March 6, 2026 | Volume: 31 | Issue: 4 | Pages: No page available

10.1093/oncolo/oyag026 | PMID 41818695 Get It

Risk Factors for Infection, Dehiscence, and Unplanned Reintubation Following Cleft Lip Repair
Gharavi, Aidin , Gibreel, Waleed , Haile, Dawit, Polites, Stephanie F. , Gibreel, Waleed , Habermann, Elizabeth B. , Mardini, Samir , Haile, Dawit T. , Gharavi, Aidin

Mayo Clinic

The Cleft Palate Craniofacial Journal | February 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/10556656261424581 | PMID 41739524 Get It

Objective We sought to characterize factors associated with postoperative complications in patients undergoing primary cleft lip repair (CLR). Design The National Surgical Quality Improvement Program-Pediatric database was queried to identify patients under 12 months old undergoing CLR using CPT codes. Multivariable analysis was conducted to characterize complications and associated comorbidities. Setting A multicenter sample. Patients/Participants A total of 11 957 cases (81.9% unilateral CLR and 18.1% bilateral CLR) were identified. Interventions None. Main Outcomes/Measures The postoperative outcomes of significance were surgical site infection (SSI), wound dehiscence, and unplanned reintubation within 30 days of CLR. Results The cohort had a mean age of 4.7 ± 2.0 months and a median American Society of Anesthesiologists classification of 2. SSIs occurred in 0.6% of cases and were independently associated with bilateral cleft anatomy (OR 2.16, P = .003) and longer anesthesia time (OR per minute: 1.004, P = .009). Wound dehiscence occurred in 0.4% of patients and was independently associated with bilateral cleft anatomy (OR 4.03, P < .001) but was associated with shorter anesthesia duration (OR per minute: 0.991, P < .001). Unplanned reintubation occurred in 0.2% of cases, with these patients having significantly higher rates of multiple comorbidities. Conclusion Wound dehiscence, SSI, and unplanned reintubation were rare complications following CLR. Patients with a bilateral cleft lip had increased odds of both SSI and wound dehiscence.
Patterns of care and clinical outcomes in systemic peripheral T-cell lymphoma: the LEO-MER prospective cohort study
Ruan, Jia , Chen, Zhengming , Larson, Melissa C, Bennani, N Nora, Allen, Pamela B. , Mou, Eric , Wallace, Danielle , Mehta-Shah, Neha, Lossos, Izidore S, Castillo, Luis E Malpica, Vega, Francisco, Inghirami, Giorgio GA, Pongas, Georgios , Akkad, Neha, Casulo, C., Martin, Peter, Cohen, Jonathon B. , Habermann, Thomas M, Maurer, Matthew J., Leonard, John P, Friedberg, Jonathan W. , Cerhan, James R, Flowers, Christopher R, Feldman, Andrew L, Bennani, N. Nora , Chen, Zhengming , Malpica, Luis , Bennani, N Nora , Allen, Pamela Blair , Mehta-Shah, Neha , Lossos, Izidore S , Malpica Castillo, Luis E , Vega, Francisco , Inghirami, Giorgio , Casulo, Carla , Cohen, Jonathon B , Maurer, Matthew , Kahl, Brad S , Cerhan, James R , Flowers, Christopher R , Feldman, Andrew L , Mou, Eric , Wallace, Danielle S , Larson, Melissa C. , Mehta–Shah, Neha , Lossos, Izidore S. , Castillo, Luis Enrique Malpica , Jaye, David L. , Inghirami, Giorgio , Akkad, Neha , Casulo, Carla , Habermann, Thomas M. , Leonard, John P. , Kahl, Brad S. , Cerhan, James R. , Flowers, Christopher R. , Feldman, Andrew L.

Mayo Clinic

Blood Advances | February 18, 2026 | Volume: 10 | Issue: 10 | Pages: 3480-3493

10.1182/bloodadvances.2025018455 | PMID 41707114 Get It

Abstract Few prospective benchmark studies exist to characterize the evolving contemporary real-world practice for peripheral T-cell lymphoma (PTCL). We report the patterns of first-line care and outcomes for 720 patients with systemic PTCL enrolled in 2 related prospective cohort studies, Lymphoma Epidemiology of Outcomes (LEO) from 2015 to 2020 and Molecular Epidemiology Resource (MER) from 2002 to 2015, both followed to 2024. The primary end points were event-free survival (EFS) and overall survival (OS) using Kaplan-Meier estimator and Cox regression model. Secondary end points included correlations of clinical and treatment factors with survival. The most common induction regimens were CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) based (70%), given as CHOP (36%), CHOP plus etoposide (23%), or CHOP-like plus novel agents (11.5%, including 5% BV-CHP [brentuximab plus cyclophosphamide, doxorubicin, and prednisone]). Consolidative autologous stem cell transplant was performed in 102 patients (14%). Within nodal PTCL, EFS and OS were adversely associated with International Prognostic Index 2 to 5, prognostic index for T-cell lymphoma score 1 to 4, and non–anaplastic large-cell lymphoma (ALCL) subtypes. Within LEO, which captured increasing first-line etoposide and brentuximab vedotin, adding etoposide to CHOP was associated with better OS in anaplastic lymphoma kinase-negative ALCL. BV-CHP showed a trend toward OS improvement in ALCL. Patients failing EFS6 and EFS24 had 5-year subsequent OS of 12% and 17%, respectively. The inferior outcomes in non-ALCL subtypes and patients failing EFS6 and EFS24 highlight unmet needs with CHOP-based induction, where clinical trials with targeted therapy should be prioritized. This trial was registered at www.clinicaltrials.gov as NCT02736357.
ACS NSQIP Matched Cohort Study of Gender-Affirming Versus Benign Hysterectomy
Narayanamoorthy, Sujatha , Habermann, Elizabeth, Occhino, John A. , Hanson, Kristine T. , Occhino, John, Habermann, Elizabeth B.

Mayo Clinic

Urogynecology | February 2, 2026 | Volume: 32 | Issue: 3 | Pages: 190-201

10.1097/spv.0000000000001784 | PMID 41712276 Get It

Importance As gender-affirming care expands, hysterectomies for gender dysphoria are increasing, but data comparing outcomes to benign hysterectomies remain limited. Objectives The objectives of this study were to compare perioperative characteristics and 30-day outcomes between transgender and gender diverse individuals (TGDI) undergoing gender-affirming hysterectomy (GAH) and patients undergoing hysterectomy for benign indications, by surgical approach. Study Design This was a retrospective cohort study using the American College of Surgeons National Surgical Quality Improvement Program data (October 2015–December 2022). TGDI undergoing GAH were identified by gender dysphoria diagnosis and hysterectomy Current Procedural Terminology codes. Approaches included abdominal hysterectomy (AH), laparoscopic/robotic hysterectomy (L/RH), laparoscopically assisted vaginal hysterectomy (LAVH), and vaginal hysterectomy (VH). A matched cohort was created based on demographics and comorbidities. Primary outcomes were operative time, length of stay (LOS), and 30-day complications. Results A total of 975 TGDI undergoing GAH were included; 82% of GAHs were minimally invasive, mostly L/RH. GAH represented 0.7% of all benign hysterectomies, increasing over time ( P <0.001). TGDI (970) were matched to controls. In L/RH, TGDI had longer operative times (113 vs 97 min, P <0.001) but shorter LOS (0 vs 1 d, P <0.001). Similar patterns were seen in VH: longer operative times (103 vs 62 min, P <0.001) and shorter LOS (0 vs 1 d, P =0.018). In AH, TGDI had shorter LOS (1 vs 2 d, P =0.006) with similar operative times. No significant differences were found in LAVH or complications across groups. Conclusion GAH is safe with perioperative outcomes comparable to benign hysterectomy. TGDI experience shorter hospital stays and low complication rates. Promoting minimally invasive and vaginal approaches can enhance equitable, high-quality care for TGDI.
National Cancer Statistics: American College of Surgeons Cancer Programs Annual Report from 2022 Participant User File
Habermann, Elizabeth B, Day, Courtney N. , Palis, Bryan E., Boffa, Daniel, Alanee, Shaheen , Habermann, Elizabeth B. , Boffa, Daniel J. , Hieken, Tina J. , Weigel, Ronald J. , Boughey, Judy C.

Mayo Clinic

Journal of the American College of Surgeons | January 21, 2026 | Volume: 242 | Issue: 6 | Pages: 1614-1630

10.1097/xcs.0000000000001747 | PMID 41562441 Get It

Primary Breast MALT Lymphoma: Clinical Features and Outcomes From a Single‐Institution Experience at Mayo Clinic
Alnughmush, Ahmed , Atallah‐Yunes, Suheil Albert , Hellou, Tamer , Habermann, Thomas M., Wang, Yucai, Munoz, Javier, Madiha, Iqbal, King, R., Breen, William G. , Villasboas, Jose C., Witzig, Thomas E., Ansell, S. M., Nowakowski, Grzegorz S. , Habermann, Thomas M. , Habermann, Thomas , Atallah-Yunes, Albert , Witzig, T.E. , Ansell, Stephen M.

Mayo Clinic

American Journal of Hematology | December 30, 2025 | Volume: 101 | Issue: 3 | Pages: 639-643

10.1002/ajh.70178 | PMID 41462033 Get It

Comprehensive analysis of subtype-specific outcomes and management in Castleman disease: a 20-year cohort study
Habermann, T. M., Gertz, Morie A, Porrata, Luis, Johnston, Patrick B. , Lin, Y., Buadi, Francis K. , Dingli, David , Wang, Yucai, Leung, Nelson, Kourelis, Taxiarchis , Witzig, TE, Warsame, Rahma , Cook, Joselle, Sher, Taimur , Gertz, Morie A. , Leung, Nelson , Wang, Yucai , Gertz, Morie A , Buadi, Francis K , Wang, Yucai , Leung, Nelson , Kourelis, Taxiarchis , Witzig, T.E. , Warsame, Rahma , Cook, Joselle M , Rosenthal, Allison C, Tun, Han W , Dispenzieri, Angela , Dingli, David , Nishimura, Yoshito , Cook, Joselle , Rosenthal, Allison , Tun, Han W. , Dispenzieri, Angela

Mayo Clinic

Blood Advances | December 24, 2025 | Volume: 10 | Issue: 5 | Pages: 1487-1496

10.1182/bloodadvances.2025018324 | PMID 41441992 Get It

Abstract Castleman disease (CD) is a heterogeneous group of lymphoproliferative disorders anatomically classified by distribution (unicentric CD [UCD], oligocentric CD [oligoCD], or multicentric CD [MCD]). Human herpes virus 8–negative MCD is called idiopathic MCD (iMCD), which includes clinical subtypes with varying phenotypes and responses: TAFRO (thrombocytopenia, anasarca, fever, renal dysfunction and/or reticulin fibrosis, and organomegaly), IPL (idiopathic plasmacytic lymphadenopathy), and not otherwise specified. OligoCD has recently emerged as an intermediate form between UCD and MCD, with unclear clinical behavior, and IPL has not been validated in a Western cohort. We retrospectively analyzed 217 patients with CD evaluated at our institution between January 2004 and August 2024. Survival probabilities were compared using log-rank tests. Overall, 57% had UCD, 20% had oligoCD, and 23% had iMCD. Patients with oligoCD and iMCD more frequently exhibited systemic symptoms than those with UCD. Patients with oligoCD and iMCD had significantly shorter event-free survival (EFS) of 8.9 and 2.3 years, respectively, than those with UCD (not reached; P&lt; .001 and P&lt; .02). Among iMCD subtypes, iMCD-IPL demonstrated a longer EFS than iMCD-TAFRO (P = .02), with no deaths during the follow-up periods. The results validate oligoCD and iMCD-IPL as new subtypes in this Western cohort. The survival outcome in oligoCD was intermediate between UCD and iMCD, with only a subset of patients with oligoCD requiring systemic therapy. iMCD-IPL had a favorable survival outcome in this US cohort, similar to what has been reported in non-Western countries. Tailoring treatment strategies to disease subtypes and vigilant monitoring of oligoCD for progression may improve survival outcomes in CD.